1 in 5 people worldwide at risk of severe Covid-19: Lancet study | WeForNews | Latest News, Blogs 1 in 5 people worldwide at risk of severe Covid-19: Lancet study – WeForNews | Latest News, Blogs
Connect with us

Disaster

1 in 5 people worldwide at risk of severe Covid-19: Lancet study

This risk varies from less than one per cent of people under 20 to nearly 20 per cent of those aged 70 or older, rising to more than 25 per cent in males over 70.

Published

on

Coronavirus

London, June 16 : An estimated 1.7 billion people have at least one of the underlying health conditions that could increase their risk of severe Covid-19 if infected, according to a global study, published in The Lancet Global Health journal.

“We hope our estimates will provide useful starting points for designing measures to protect those at increased risk of severe disease,” said study researcher Andrew Clark from the London School of Hygiene & Tropical Medicine (LSHTM) in the UK.

“This might involve advising people with underlying conditions to adopt social distancing measures appropriate to their level of risk, or prioritising them for vaccination in the future,” Clark added.

The researchers estimated that four per cent of the world”s population (349 million of 7.8 billion people) would require hospitalisation if infected, suggesting that the increased risk of severe Covid-19 could be quite modest for many with underlying conditions.The new study provides global, regional and national estimates for the number of people with underlying health conditions.

The research team caution that they focused on underlying chronic conditions and didn”t include other possible risk factors for Covid-19 that are not yet included in all guidelines, such as ethnicity and socioeconomic deprivation. Their estimates are therefore unlikely to be exhaustive but serve as a starting point for policy-makers.

The authors based their estimates on disease prevalence data from the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) 2017, UN population estimates for 2020 and the list of underlying health conditions relevant to COVID-19, as defined by current guidelines. They analysed the number of people with an underlying condition by age group, sex and country for 188 countries.

To help determine the degree of increased risk, the researchers also provided separate estimates of the proportion of all people (with and without underlying conditions) who would require hospitalisation if infected. The authors calculated those at high risk using infection hospitalisation ratios for Covid-19 and made adjustments for differences between countries.

According to the study, globally, less than five per cent of people aged under 20 years, but more than 66 per cent of those aged 70 and above, have at least one underlying condition that could increase their risk of severe Covid-19.

Among the working-age population (15 to 64 years), 23 per cent are estimated to have at least one underlying condition. The authors estimated that 349 million people worldwide are at high risk of severe Covid-19, meaning they would require hospital treatment if infected.

This risk varies from less than one per cent of people under 20 to nearly 20 per cent of those aged 70 or older, rising to more than 25 per cent in males over 70.

The findings showed that in all age groups under 65, around twice the number of men as women would require hospitalisation. Above 65 years, the ratio becomes less marked because women are over-represented in older age groups due to longer life expectancy.

Disaster

COVID-19 pandemic “once in a century”, but still “in our hands”: WHO

“I’m not saying there is no solution now. Whatever happens in the next few months or years, I also believe that it’s in our hands,” he said.

Published

on

By

Tedros Adhanom Ghebreyesus WHO

Geneva, Aug 4 : The chief of the World Health Organization (WHO) said that the COVID-19 pandemic is “a once-in-a-century health crisis,” but it is still “in our hands.”

WHO Director-General Tedros Adhanom Ghebreyesus said at a virtual press conference on Monday that the world has never seen anything like this pandemic for decades, and its effects might last for decades more, Xinhua news agency reported.

“Since we started probably recording, this is the first ever coronavirus-caused pandemic which has two dangerous combinations: it moves fast, and at the same time it’s a killer,” the WHO chief explained.

However, he noted, although the crisis is very severe, there are still solutions and hopes.

“I’m not saying there is no solution now. Whatever happens in the next few months or years, I also believe that it’s in our hands,” he said.

“Since the outbreak started, many countries have shown that it can be controlled, or serious transmission can be suppressed,” Tedros said, adding that he has mentioned many such countries in the past, including Spain, Italy, China and South Korea.

Continue Reading

Disaster

One person is dying of COVID-19 every seven minutes in Iran: state TV

The report said that Iran’s official coronavirus figures were based only on the number of deaths in hospitals and those who had already tested positive for the coronavirus.

Published

on

Iran Covid Case

DUBAI : One person is dying from COVID-19 every seven minutes in Iran, state television said on Monday, as the Health Ministry reported 215 new deaths from the disease and state media warned of a lack of proper social distancing.

Health Ministry spokesman Sima Sadat Lari was quoted by the state TV as saying the 215 deaths in the past 24 hours took the combined death toll to 17,405 in Iran, and the number of confirmed cases rose by 2,598 to 312,035.

State television showed several Iranians in a busy Tehran street without wearing face masks or social distancing.

Some experts have doubted the accuracy of Iran’s official coronavirus tolls. A report by the Iranian parliament’s research centre in April suggested that the coronavirus tolls might be almost twice as many as those announced by the health ministry.

The report said that Iran’s official coronavirus figures were based only on the number of deaths in hospitals and those who had already tested positive for the coronavirus.

British broadcaster BBC reported on Monday that, based on data from an anonymous source, the number of deaths in Iran might be three times higher than officially reported. Iranian health authorities denied the report and said there had been no covebakingr-up.

With COVID-19 deaths surging since restrictions were eased in mid-April, Iranian authorities have said measures to curb the spread of COVID-19 will be reimposed if health regulations are not observed. Since last month, wearing face masks in public places and covered spaces has been mandatory.

Iran’s National Coronavirus Combat Taskforce was expected to announce later on Monday whether nationwide university entrance examinations, with over 1 million participants, will take place in August. Many Iranians have called on social media for the examinations to be postponed.

Continue Reading

Disaster

Jubilant Life Sciences launches remdesivir for injection

‘JUBI-R’ will require to be administered intravenously in a hospital setting under the supervision of a medical practitioner.

Published

on

remdesivir injection

New Delhi, Aug 3 : Jubilant Life Sciences Ltd on Monday announced that its subsidiary, Jubilant Generics, has launched remdesivir for injection, under the brand name ‘JUBI-R’, in the Indian market at a price of Rs 4,700 per vial of 100 mg.

The company said it will make the drug available to over 1,000 hospitals providing Covid-19 treatment in India through its distribution network.

In May this year, Jubilant entered into a non-exclusive Licensing Agreement with Gilead Sciences that granted it the right to register, manufacture and sell Gilead’s investigational drug remdesivir in 127 countries including India.

Remdesivir is an antiviral drug that has received Emergency Use Authorisation (EUA) by the US FDA for treatment of suspected or laboratory confirmed Covid-19 in adults and children hospitalised with severe disease.

On July 20, Jubilant received approval from the Drug Controller General of India (DCGI) to manufacture and market the investigational antiviral drug remdesivir (‘JUBI-R’) for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe Covid-19.

“The company’s ability to launch this product in such short timelines highlights our R&D and manufacturing capabilities and our continued commitment to provide leading healthcare solutions,” Shyam Bhartia, Chairman & Managing Director and Hari Bhartia, Co-Chairman, Jubilant Pharma Ltd, said in a statement.

“Through the Jubilant Bhartia Foundation, we will distribute the drug on compassionate basis to save precious lives of people through unique programmes.”

‘JUBI-R’ will require to be administered intravenously in a hospital setting under the supervision of a medical practitioner.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.